Cross-Disciplinary Team From Harvard and Dana-Farber Brings Novel Therapeutic Cancer Vaccine to Human Clinical Trials
Dana-Farber Cancer InstituteA team from Harvard and Dana-Farber has launched a Phase I clinical trial of a therapeutic melanoma vaccine designed to reprogram a patient's immune system to destroy tumors. The vaccine consists of a small disk-like, biodegradable sponge that's infused with signaling molecules and components of the patient's tumor.